Table 1.
Characteristics of 121 patients with advanced cancers
| Characteristic | Total No. of patients | No. of patients with KRASG12/G13 mutation in FFPE tumor (%) | No. of patients with KRASG12/G13 mutation in plasma cfDNA* (%) |
|---|---|---|---|
| All | 121 | 88 (73) | 78 (64) |
| Sex | |||
| Male | 68 | 53 (78) | 47 (69) |
| Female | 53 | 35 (66) | 31 (58) |
| Race | |||
| Caucasian | 86 | 60 (70) | 56 (65) |
| African American | 21 | 18 (86) | 13 (62) |
| Hispanic | 13 | 10 (77) | 9 (69) |
| Asian | 1 | 0 (0) | 0 (0) |
| Disease | |||
| Colorectal cancer | 71 | 59 (83) | 53 (75) |
| Non-small cell lung cancer | 14 | 10 (71) | 7 (50) |
| Melanoma | 10 | 1 (10) | 2 (20) |
| Appendiceal cancer | 6 | 6 (100) | 4 (67) |
| Pancreatic cancer | 5 | 5 (100) | 5 (100) |
| Ovarian cancer | 5 | 3 (60) | 3 (60) |
| Uterine cancer | 3 | 2 (67) | 2 (67) |
| Breast cancer | 3 | 1 (33) | 2 (67) |
| Duodenal cancer | 1 | 1 (100) | 0 (0) |
| Squamous head and neck cancer | 1 | 0 (0) | 0 (0) |
| Papillary thyroid cancer | 1 | 0 (0) | 0 (0) |
| Erdheim–Chester histiocytosis | 1 | 0 (0) | 0 (0) |
| Method of tumor KRASG12/G13 testing | |||
| PCR | 58 | 42 (72) | 37 (64) |
| NGS | 50 | 36 (72) | 33 (66) |
| MassARRAY | 13 | 10 (77) | 8 (62) |
FFPE, formalin-fixed, paraffin-embedded; cfDNA, cell-free DNA; PCR, polymerase chain reaction; NGS, next-generation sequencing.
*
Mutations were detected by testing 16 ng of cfDNA using the KRASG12/G13 multiplex probe.